Dr. Gregory E. Halligan
Claim this profileSaint Christopher's Hospital for Children
About Gregory E. Halligan
Education:
- Earned an MD from Jefferson Medical College, Philadelphia, PA, in 1987.
Experience:
- Completed Pediatric Residency at St. Christopher's Hospital for Children, Philadelphia, PA (1987-1990).
- Undertook a Fellowship in Pediatric Hematology/Oncology at St. Jude Children's Research Hospital, Memphis, TN (1990-1993).
- Has been serving as an Attending Physician in Pediatric Hematology/Oncology at St. Christopher's Hospital for Children since 1993.
Area of expertise
Cancer
Gregory E. Halligan has run 9 trials for Cancer. Some of their research focus areas include:
Brain Tumor
Gregory E. Halligan has run 9 trials for Brain Tumor. Some of their research focus areas include:
Affiliated Hospitals
Saint Christopher's Hospital For Children
Drexel University School Of Medicine
Clinical Trials Gregory E. Halligan is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting
2 awards
Phase 3
Selinexor + Radiation
for Brain Cancer
This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
Recruiting
1 award
Phase 1 & 2
1 criteria
More about Gregory E. Halligan
Clinical Trial Related
5 years of experience running clinical trials · Led 44 trials as a Principal Investigator · 19 Active Clinical Trials
Treatments Gregory E. Halligan has experience with
- Cyclophosphamide
- Etoposide
- Radiation Therapy
- Doxorubicin Hydrochloride
- Vincristine Sulfate
- Methotrexate
Breakdown of trials Gregory E. Halligan has run
Cancer
Brain Tumor
Leukemia
Neuroblastoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gregory E. Halligan specialize in?
Gregory E. Halligan focuses on Cancer and Brain Tumor. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Gregory E. Halligan currently recruiting for clinical trials?
Yes, Gregory E. Halligan is currently recruiting for 18 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Gregory E. Halligan has studied deeply?
Yes, Gregory E. Halligan has studied treatments such as Cyclophosphamide, Etoposide, Radiation Therapy.
What is the best way to schedule an appointment with Gregory E. Halligan?
Apply for one of the trials that Gregory E. Halligan is conducting.
What is the office address of Gregory E. Halligan?
The office of Gregory E. Halligan is located at: Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania 19134 United States. This is the address for their practice at the Saint Christopher's Hospital for Children.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.